TYRA earnings date and last-quarter result: next report 2026-08-13, last quarter miss, P/E -14.03. Updated 2026-07-23.
Tyra Biosciences (TYRA) Research Hub
Tyra Biosciences (TYRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 20.42 USD (-0.15%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.03, market cap 1.86B. This hub links to the full technical, earnings and options research available for TYRA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 20.42 USD (-0.15%) |
| 52-week range | 18.25 USD – 33.43 USD |
| Trend regime | Range |
| 14-day RSI | 51.6 (Neutral) |
| Trailing P/E | -14.03 |
| Market cap | 1.86B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for TYRA
Covered Call on TYRA: how it works, illustrative setup around the real 20.42 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TYRA: how it works, illustrative setup around the real 20.42 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TYRA: how it works, illustrative setup around the real 20.42 USD price, max profit/loss, breakeven and when to use it. Educational.
TYRA technical analysis: range, last 20.42 USD, RSI 51.6, 52w range 18.25 USD–33.43 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is TYRA in?
Tyra Biosciences (TYRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TYRA in an uptrend or downtrend?
As of 2026-10-26, TYRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TYRA's trailing P/E ratio?
TYRA's trailing P/E is -14.03, with a market cap of 1.86B. See the earnings research page for full valuation detail.
When does TYRA next report earnings?
TYRA is next scheduled to report earnings on 2026-08-13.